Aytu Biopharma, Inc. AYTU
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in AYTU BIOPHARMA, INC's annual report to the U.S. Securities and Exchange Commission, filed 23 September 2025. Every sentence was checked against that document before publication.
Growth
Revenue compounded at −2.6% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 53 cents this year.
The 19-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ | ◌ | ◌ | ◌ | ◌ |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | ◌ | ◌ | ◌ | ◌ |
| EBITDA $B | −0.0 | −0.0 | 0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | ◌ | ◌ | ◌ | ◌ |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.0 | −0.0 | −0.0 | ◌ | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| EPS, diluted $ | ◌ | ◌ | ◌ | −5.11 | −74.01 | −3.48 | −3.01 | −3.48 | −15.31 | −48.30 | −323.70 | −10.07 | −0.80 | −0.01 | −0.03 | ◌ | ◌ | ◌ | ◌ |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −52.6 | −58.1 | −47.2 | −40.8 | −119.6 | −50.1 | −26.7 | −264.5 | −116.9 | −319.6 | −219.3 | −73.6 | −73.5 | — | — | — | — | −255.4 | −260.3 |
| Shares out B | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.03 | 0.13 | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | ◌ | ◌ | ◌ | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 19 of the 19 fiscal years we could check. Eight checks were skipped: the balance sheet is not tagged before 2011. Seven checks were skipped: cost of revenue is not tagged before 2014. Five checks were skipped: the share count is not tagged before 2012.